Haoxi Health Technology Limited Class A Ordinary Shares is at the forefront of the health technology sector, dedicated to transforming healthcare delivery through innovative, technology-driven solutions. By leveraging cutting-edge artificial intelligence and data analytics, the company enhances diagnostic accuracy, streamlines treatment processes, and optimizes patient management. Haoxi's strong emphasis on research and development positions it to effectively address emerging healthcare challenges, offering significant growth potential for institutional investors seeking to capitalize on advancements in this rapidly evolving market.
| Revenue (TTM) | $42.68M |
| Gross Profit (TTM) | $2.04M |
| EBITDA | $-7.05M |
| Operating Margin | -16.80% |
| Return on Equity | -16.00% |
| Return on Assets | -22.10% |
| Revenue/Share (TTM) | $1202.80 |
| Book Value | $34.36 |
| Price-to-Book | 0.15 |
| Price-to-Sales (TTM) | 0.05 |
| EV/Revenue | 0.895 |
| EV/EBITDA | 13.53 |
| Quarterly Earnings Growth (YoY) | 172.70% |
| Quarterly Revenue Growth (YoY) | 41.20% |
| Shares Outstanding | $1.90M |
| Float | 395,260 |
| % Insiders | 0.18% |
| % Institutions | 0.01% |
BEIJING, May 19, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (NASDAQ: HAO; “we” or the “Company”), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.0025 per share (the “Class A Ordinary Shares”) and Class B ordinary shares, par value $0.0025 per share (the “Class B Ordinary Shares”), at a ratio of 1-for-128.
BEIJING, May 11, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Ltd (NASDAQ: HAO) (“Haoxi” or the “Company”) today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of approximately $6.5 million of the Company's securities, including 9,000,000 Class A ordinary shares, par value $0.0025 per share (the “Shares”) and 16,999,998 pre-funded warrants, at a purchase price of $0.25 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.0026 per share.
